Abstracts tagged "Biomarkers and systemic lupus erythematosus (SLE)"

Abstract Number: 2932 • 2018 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Biomarkers Identified Using Multi-Omic and Artificial Intelligence Analysis through Interrogative Biology
Eric Grund¹, Lixia Zhang¹, Leonardo Rodrigues¹, Viatcheslav Akmaev¹, Rangaprasad Sarangarajan¹, Michael Kiebish¹, Niven Narain¹ and Gary S. Gilkeson², ¹BERG, LLC, Framingham, MA, ²Department of Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: Biomarkers for use in developing treatments and diagnostics for Systemic Lupus Erythematosus (SLE) are a large unmet need. The wide differential in patient progression…
Abstract Number: 677 • 2017 ACR/ARHP Annual Meeting
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts the Development of Organ Damage over 5 Years in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Helena Enocsson¹, Lina Wirestam¹, Jonas Wetterö¹, Thomas Skogh¹, Ian N. Bruce^2,3 and Christopher Sjöwall⁴, ¹Rheumatology, Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, Linköping, Sweden, ²Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ³NIHR Manchester Musculoskeletal Biomedical Research Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁴Department of Clinical and Experimental Medicine, Linköping University, Sweden, Linköping, Sweden
Background/Purpose: The urokinase plasminogen activator receptor (uPAR) is expressed on various cell types and plays important roles in proteolysis, migration and adhesion. Receptor shedding yields…
Abstract Number: 692 • 2017 ACR/ARHP Annual Meeting
High Plasma Factor XIII Transglutaminase Activity Inversely Correlates with SLE Disease Activity Yet Associates with Higher Carotid Artery IMT and Low CD14+CD16+ Monocyte Levels
Brian Skaggs¹, Isao Matsuura², Elaine Lourenco¹, Eloise Olmos³, Jennifer M. Grossman¹ and Maureen A. McMahon¹, ¹University of California-Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ²Department of Rheumatology, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, Japan, ³Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: The transglutaminase Factor XIII (FXIII) stabilizes blood clots through crosslinking fibrin lysine and glutamine residues at the end of the complement cascade. Enzymatic activity…
Abstract Number: 1665 • 2017 ACR/ARHP Annual Meeting
Soluble Programmed Cell Death Protein 1 As a Biomarker for Systemic Lupus Erythematosus
Shinya Hirahara, Yasuhiro Katsumata, Yasushi Kawaguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Programmed cell death protein 1 (PD-1/CD279) is a cell surface receptor that belongs to the extended CD28/CTLA-4 family and is expressed on T cells…
Abstract Number: 1866 • 2015 ACR/ARHP Annual Meeting
Fall in Dicer1 Gene Expression Flags Abnormal Lymphocyte Activation in Lupus
Olga Sanchez-Pernaute¹, Fredeswinda Romero², Maria Perez-Ferro¹, Cristina Serrano³, María J Martinez-Becerra⁴, F Javier de la Hera⁵ and Rosario Haro⁶, ¹Section for Autoimmune Diseases, Rheumatology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ²Section for Autoimmune Diseases. Rheumatology., Jiménez Díaz Foundation University Hospital, Madrid, Spain, ³Section for Autoimmune Diseases. Immunology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ⁴Immunology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ⁵Section for Autoimmune Diseases, Internal Medicine, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ⁶Section for Autoimmune Diseases. Dermatology, Jiménez Díaz Foundation University Hospital, Madrid, Spain
Background/Purpose: The integrity of the microRNA machinery is required for the normal reactivity of the immune system both during differentiation and upon antigen engagement. Dicer1…
Abstract Number: 2944 • 2015 ACR/ARHP Annual Meeting
Presepsin (sCD14 subtype) Concentration Is Elevated and Reflects Disease Activity in Systemic Lupus Erythematous Patients
Kohei Tsujimoto¹, Masaaki Fujita², Yutaka Shinkawa², Iku Shirasugi¹, Masashi Taniguchi¹, Saori Hatachi³ and Masato Yagita⁴, ¹Department of Clinical Immunology and Rheumatology, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ²Department of Clinical Immunology and Rheumatology C, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ³Department of Rheumatology, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ⁴Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan
Background/Purpose: Presepsin (sCD14 subtype) has recently been identified as a novel biomarker for predicting sepsis. Because presepsin is produced as a consequence of cellular phagocytosis,…
Abstract Number: 1848 • 2015 ACR/ARHP Annual Meeting
Increased Expression of Bruton Tyrosine Kinase in Patients with Lupus Nephritis and Its Clinic Significance
Wei Kong, Wei Deng, Xuebing Feng, Genhong Yao, Weiwei Chen, Xiaojun Tang, Yue Sun, Saisai Huang, Zhuoya Zhang, Bingyu Shi and Lingyun Sun, Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease manifested by multiorgan impairment including glomerulonephritis, cutaneous lesions and arthritis. B cells participate in the onset…
Abstract Number: 1613 • 2014 ACR/ARHP Annual Meeting
Circulating microRNAs As Candidate Biomarkers of Diagnosis in Systemic Lupus Erythematosus
Juyang Jung¹, Ja-Young Jeon², Bong-Sik Kim³, Hyoun-Ah Kim² and Chang-Hee Suh⁴, ¹Ajou university of medical school, Suwon, South Korea, ²Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ³Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ⁴Rheumatology, Ajou University School of Med, Suwon, South Korea
Background/Purpose : Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by polyclonal B-cell activation and elevated production of pathogenic autoantibodies. MicroRNAs (miRNAs) are short,…
Abstract Number: 1608 • 2014 ACR/ARHP Annual Meeting
Erythrocyte C4d and Antibodies to Anti-C1q Are Associated with Proteinuria in Lupus Nephritis
Jill P. Buyon¹, R. Ramsey-Goldman², Richard Furie³, Chaim Putterman⁴, Kenneth Kalunian⁵, John Conklin⁶, Tyler O'Malley⁷, Derren Barken⁸ and Thierry Dervieux⁹, ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵UCSD School of Medicine, La Jolla, CA, ⁶1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ⁷Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁸Exagen Diagnostics, Inc., Vista, CA, ⁹rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Biomarkers of renal response in patients with systemic lupus erythematosus (SLE) may provide clues to pathogenesis and drive translation to treatment. This study was…
Abstract Number: 866 • 2014 ACR/ARHP Annual Meeting
Heart Rate Variability: An Inflammatory Biomarker in Systemic Lupus Erythematosus
Aikaterini Thanou¹, Stavros Stavrakis², John Dyer², Stan Kamp³, Melissa E. Munroe⁴, David Albert⁵, Judith A. James⁶ and Joan T. Merrill³, ¹Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵AliveCor, Inc., San Francisco, CA, ⁶Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Heart rate variability (HRV) is a marker of vagus nerve activity and can be easily obtained with minimal technical expertise in the outpatient setting,…
Abstract Number: 2727 • 2013 ACR/ARHP Annual Meeting
Immunologic and Inflammatory Markers Of Impending Disease Flare In Systemic Lupus Erythematosus Patients Not Taking Immunosuppressive Medications In The Biomarkers Of Lupus Disease (BOLD) Study
Joel M. Guthridge¹, Mikhail G. Dozmorov², Melissa E. Munroe³, Krista M. Bean¹, Sudhakar T. Sridharan⁴, Joan T. Merrill⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clincial Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴BioTherapeutics R&D, Pfizer Inc, Collegeville, PA, ⁵Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a clinically heterogeneous disorder characterized by a waxing and waning clinical course. Predictors of clinical disease flare have been…
Abstract Number: 1864 • 2013 ACR/ARHP Annual Meeting
Immunologic Markers and Molecular Mechanisms Associated With Increased Systemic Lupus Erythematosus Activity In Patients Not Taking Immunosuppressive Medications
Mikhail G. Dozmorov¹, Cory Giles², Krista M. Bean², Nicolas Dominguez², Jonathan D. Wren³, Joan T. Merrill⁴, Judith A. James⁵ and Joel M. Guthridge², ¹Arthritis and Clincial Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The course of systemic lupus erythematosus (SLE) is characterized by exacerbations (or flares) and remissions of disease activity. Predicting which patients are likely to…
Abstract Number: 2280 • 2012 ACR/ARHP Annual Meeting
Serum Metabolomics As a Novel Diagnostic Approach for Systemic Lupus Erythematosus
Jun Saegusa¹, Yasuhiro Irino², Masaru Yoshida², Shino Tanaka¹, Yoshinori Kogata¹, Goichi Kageyama¹, Seiji Kawano¹, Goh Tsuji³, Shunichi Kumagai³ and Akio Morinobu¹, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²The Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ³The Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan
Background/Purpose: Metabolomics, or metabolome analysis, is the comprehensive study of low-molecular-weight metabolites. The metabolome represents the metabolite profiles of all the cellular processes in a…
Abstract Number: 2248 • 2012 ACR/ARHP Annual Meeting
Serum Phosphatidylserine-Specific Phospholipase A1 (PS-PLA1) Identified As a Novel Biomarker for Systemic Lupus Erythematosus (SLE)
Tetsuji Sawada¹, Kazuhiro Nakamura², Ryunosuke Ohkawa², Aki Shoji¹, Koichiro Tahara¹, Haeru Hayashi¹, Eri Kimura¹, Koji Igarashi³, Junken Aoki⁴ and Yutaka Yatomi⁵, ¹Rheumatology, Tokyo Medical University, Tokyo, Japan, ²Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan, ³AIA Research Group, TOSOH Corporation, Kanagawa, Japan, ⁴Department of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan, ⁵Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: Lysophosphatidylserine (LPS), which is a degraded form of phosphatidylserine (PS), is an acidic lyso-glycerophospholipid, similar to lysophosphatidic acid (LPA). LPS is known to mediate…
Abstract Number: 2256 • 2012 ACR/ARHP Annual Meeting
A Population of IL-21 Producing CD4⁺ T Cells Correlates with Disease Damage in Systemic Lupus Erythematosus (SLE) Patients
Babak Noamani¹, Stacey Morrison², Dafna D. Gladman³, Jorge Sanchez-Guerrero⁴, Murray B. Urowitz⁵, Joan E. Wither⁶ and Carolina Landolt-Marticorena⁷, ¹Genetics and developmental biology, Toronto Western Research Institute, Toronto, ON, Canada, ²Div Rheumatology Rm MP-10-304, The Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴UHN Toronto Western Hospital, Toronto, ON, Canada, ⁵Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: SLE mice models implicate IL-21, a T cell-derived cytokine, in disease pathogenesis with cytokine over-expression promoting the development of auto-antibodies and lupus-like clinical syndromes.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].